| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Johns Hopkins Medical Institutions, Baltimore, Maryland 21287 [M. V. B., M. G., A. M., E. M., M. D., L. R., S. C. Y., A. A. F., S. B. B., J. G. H.]; Tokyo Medical and Dental University, Tokyo, Japan [Y. A.]; University of Texas M. D. Anderson Cancer Center, Houston, Texas [T-T. W.]; University Hospital of Antwerp, Antwerp, Belgium [P. G.]; and Union Memorial Hospital, Baltimore, Maryland [R. F. H.]
Purpose: We investigated aberrant methylation patterns in esophageal adenocarcinoma and correlated the findings to patient survival and tumor recurrence.
Experimental Design: Gene promoter methylation was performed in 82 samples from 41 esophagectomy patients consisting of 41 adenocarcinoma samples, each with its adjacent nonmalignant tissue, which included one sample with Barretts metaplasia. The methylation status of seven genes was determined. Epigenetic silencing was confirmed using immunohistochemical staining. Kaplan-Meier plots were constructed using disease-specific survival as the primary end point and the interval from surgery to tumor recurrence as the secondary end point. The association of clinicopathological and biomolecular risk factors to survival and recurrence was performed using the Log-rank test and Cox proportional hazards model for multivariate analysis.
Results: Methylation frequencies of the genes analyzed were APC, 68%; E-cadherin, 66%; O6-methylguanine DNA methyltransferase, 56%; ER, 51%; p16, 39%; DAP-kinase, 19%; and TIMP3, 19%. DNA methylation of some genes individually showed only trends toward diminished survival, whereas patients whose tumors had >50% of their gene profile methylated had both significantly poorer survival (P = 0.04) and earlier tumor recurrence (P = 0.05) than those without positive methylation. By multivariate analysis, the hazard ratios (HRs) with positive methylation status were more powerful predictors of survival [HR 2.7 (1.14–6.45; 95% confidence interval)] and tumor recurrence [HR 2.5 (1.11–5.6)] than age (HR 2.03 and 1.96, respectively) or stage (HR 1.48 and 1.67, respectively).
Conclusions: Our data suggest that positive methylation status for multiple genes in esophageal adenocarcinoma is a predictor of poor prognosis.
Commentary
Clin. Cancer Res. 2003 9: 2879-2881.
This article has been cited by other articles:
|
|
 |
|
  J. Geli, N. Kiss, M. Karimi, J.-J. Lee, M. Backdahl, T. J. Ekstrom, and C. Larsson Global and Regional CpG Methylation in Pheochromocytomas and Abdominal Paragangliomas: Association to Malignant Behavior Clin. Cancer Res., May 1, 2008; 14(9): 2551 - 2559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Brock, C. M. Hooker, E. Ota-Machida, Y. Han, M. Guo, S. Ames, S. Glockner, S. Piantadosi, E. Gabrielson, G. Pridham, et al. DNA Methylation Markers and Early Recurrence in Stage I Lung Cancer N. Engl. J. Med., March 13, 2008; 358(11): 1118 - 1128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Kim, K. Yamashita, Y. K. Chae, Y. Tokumaru, X. Chang, M. Zahurak, M. Osada, H. L. Park, A. Chuang, J. A. Califano, et al. A Promoter Methylation Pattern in the N-Methyl-D-Aspartate Receptor 2B Gene Predicts Poor Prognosis in Esophageal Squamous Cell Carcinoma Clin. Cancer Res., November 15, 2007; 13(22): 6658 - 6665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Zhang, K. Li, L. Wei, Z. Li, P. Yu, L. Teng, K. Wu, and J. Zhu p300 expression repression by hypermethylation associated with tumour invasion and metastasis in oesophageal squamous cell carcinoma J. Clin. Pathol., November 1, 2007; 60(11): 1249 - 1253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Jin, A. Olaru, J. Yang, F. Sato, Y. Cheng, T. Kan, Y. Mori, C. Mantzur, B. Paun, J. P. Hamilton, et al. Hypermethylation of Tachykinin-1 Is a Potential Biomarker in Human Esophageal Cancer Clin. Cancer Res., November 1, 2007; 13(21): 6293 - 6300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Maeda, T. Chiba, S. Kawashiri, T. Satoh, and K. Imai Epigenetic Inactivation of I{kappa}B Kinase-{alpha} in Oral Carcinomas and Tumor Progression Clin. Cancer Res., September 1, 2007; 13(17): 5041 - 5047. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Napieralski, K. Ott, M. Kremer, K. Becker, A.-L. Boulesteix, F. Lordick, J. R. Siewert, H. Hofler, and G. Keller Methylation of Tumor-Related Genes in Neoadjuvant-Treated Gastric Cancer: Relation to Therapy Response and Clinicopathologic and Molecular Features Clin. Cancer Res., September 1, 2007; 13(17): 5095 - 5102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Zagorowicz and J. Jankowski Molecular changes in the progression of Barrett's oesophagus Postgrad. Med. J., August 1, 2007; 83(982): 529 - 535. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Martinez, F. Setien, C. Voelter, S. Casado, M. P. Quesada, G. Schackert, and M. Esteller CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme Carcinogenesis, June 1, 2007; 28(6): 1264 - 1268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Lagarde, F. J. W. ten Kate, D. J. Richel, G. J. A. Offerhaus, and J. J. B. van Lanschot Molecular Prognostic Factors in Adenocarcinoma of the Esophagus and Gastroesophageal Junction Ann. Surg. Oncol., February 1, 2007; 14(2): 977 - 991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Zhang, Z. Li, Y. Cheng, F. Jia, R. Li, M. Wu, K. Li, and L. Wei CpG Island Methylator Phenotype Association with Elevated Serum {alpha}-Fetoprotein Level in Hepatocellular Carcinoma Clin. Cancer Res., February 1, 2007; 13(3): 944 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Guo, J. Ren, M. G. House, Y. Qi, M. V. Brock, and J. G. Herman Accumulation of Promoter Methylation Suggests Epigenetic Progression in Squamous Cell Carcinoma of the Esophagus Clin. Cancer Res., August 1, 2006; 12(15): 4515 - 4522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Worsham, K. M. Chen, V. Meduri, A. O. H. Nygren, A. Errami, J. P. Schouten, and M. S. Benninger Epigenetic events of disease progression in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg, June 1, 2006; 132(6): 668 - 677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Brena, H. Auer, K. Kornacker, B. Hackanson, A. Raval, J. C. Byrd, and C. Plass Accurate quantification of DNA methylation using combined bisulfite restriction analysis coupled with the Agilent 2100 Bioanalyzer platform Nucleic Acids Res., February 7, 2006; 34(3): e17 - e17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Brock, C. M. Hooker, R. Yung, M. Guo, Y. Han, S. E. Ames, D. Chang, S. C. Yang, D. Mason, M. Sussman, et al. Can We Improve the Cytologic Examination of Malignant Pleural Effusions Using Molecular Analysis? Ann. Thorac. Surg., October 1, 2005; 80(4): 1241 - 1247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. O. Hoque, E. Rosenbaum, W. H. Westra, M. Xing, P. Ladenson, M. A. Zeiger, D. Sidransky, and C. B. Umbricht Quantitative Assessment of Promoter Methylation Profiles in Thyroid Neoplasms J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4011 - 4018. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Safar, H. Spencer III, X. Su, M. Coffey, C. A. Cooney, L. D. Ratnasinghe, L. F. Hutchins, and C.-Y. Fan Methylation Profiling of Archived Non-Small Cell Lung Cancer: A Promising Prognostic System Clin. Cancer Res., June 15, 2005; 11(12): 4400 - 4405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Melnikov, R. B. Gartenhaus, A. S. Levenson, N. A. Motchoulskaia, and V. V. Levenson (Chernokhvostov) MSRE-PCR for analysis of gene-specific DNA methylation Nucleic Acids Res., June 8, 2005; 33(10): e93 - e93. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Mandelker, K. Yamashita, Y. Tokumaru, K. Mimori, D. L. Howard, Y. Tanaka, A. L. Carvalho, W.-W. Jiang, H. L. Park, M. S. Kim, et al. PGP9.5 Promoter Methylation Is an Independent Prognostic Factor for Esophageal Squamous Cell Carcinoma Cancer Res., June 1, 2005; 65(11): 4963 - 4968. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Koga, Y. Kitajima, A. Miyoshi, K. Sato, K. Kitahara, H. Soejima, and K. Miyazaki Tumor Progression Through Epigenetic Gene Silencing of O6-Methylguanine-DNA Methyltransferase in Human Biliary Tract Cancers Ann. Surg. Oncol., May 1, 2005; 12(5): 354 - 363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. Laird Cancer epigenetics Hum. Mol. Genet., April 15, 2005; 14(suppl_1): R65 - R76. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. An, I.-S. Choi, J. C. Yao, S. Worah, K. Xie, P. F. Mansfield, J. A. Ajani, A. Rashid, S. R. Hamilton, and T.-T. Wu Prognostic Significance of CpG Island Methylator Phenotype and Microsatellite Instability in Gastric Carcinoma Clin. Cancer Res., January 15, 2005; 11(2): 656 - 663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Fackler, M. McVeigh, J. Mehrotra, M. A. Blum, J. Lange, A. Lapides, E. Garrett, P. Argani, and S. Sukumar Quantitative Multiplex Methylation-Specific PCR Assay for the Detection of Promoter Hypermethylation in Multiple Genes in Breast Cancer Cancer Res., July 1, 2004; 64(13): 4442 - 4452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. J. Issa Methylation and Prognosis: Of Molecular Clocks and Hypermethylator Phenotypes Clin. Cancer Res., August 1, 2003; 9(8): 2879 - 2881. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
